Research Summary Editorial Supplemental content Author Affiliations: Author affiliations are listed at the end of this article. Corresponding Author: Rohan Wijesurendra, MB, BChir MA (Cantab), MSc, DPhil (Oxon), Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Richard Doll Building, Oxford, OX3 7LF, United Kingdom (rohan.wijesurendra @ndph.ox.ac.uk). Research JAMA | Original Investigation (Reprinted) E1 © 2026 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies. Downloaded from jamanetwork.com by Liberty University, kxdigital.biz.id o on 05/26/2026 A trial fibrillation (AF) affects more than 50 million individualsworldwide1andrepres entsaburgeoningpublichealthepidemic.2,3Prevalencerisessharplywithadvancing age,4 and AF is frequently accompanied by physical frailty and reduced functional capacity in older adults.5,6 Excess body weight has emerged as the strongest modifiable risk factor for incident AF, with increased body mass index (BMI) independently associated with AF onset, progression, and recurrence.7-11 Weight loss has a class I recommendation in clinical guidelines for patients with obesity and AF, targeting a loss of 10% or more of body weight.12,13 Structured interventions based on low-energy diets (800-1200 kcal/d) can achieve meaningful weight loss, better glycemic control, and lower blood pressure in individuals with ov
Download PDF: https://yanta.eu.org/allvqg
